ES2256493T3 - Procedimiento para la preparacion de un ligando tiazol ppar y polimorfos del mismo. - Google Patents

Procedimiento para la preparacion de un ligando tiazol ppar y polimorfos del mismo.

Info

Publication number
ES2256493T3
ES2256493T3 ES02747330T ES02747330T ES2256493T3 ES 2256493 T3 ES2256493 T3 ES 2256493T3 ES 02747330 T ES02747330 T ES 02747330T ES 02747330 T ES02747330 T ES 02747330T ES 2256493 T3 ES2256493 T3 ES 2256493T3
Authority
ES
Spain
Prior art keywords
compound
formula
ppar
procedure
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02747330T
Other languages
English (en)
Spanish (es)
Inventor
Thierry Glaxosmithkline Boyer
Caroline Jane Glaxosmithkiline Day
Andrew Jonathan Glaxosmithkline Whitehead
Richard Anthony Henson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2256493T3 publication Critical patent/ES2256493T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
ES02747330T 2001-05-31 2002-05-29 Procedimiento para la preparacion de un ligando tiazol ppar y polimorfos del mismo. Expired - Lifetime ES2256493T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0113232 2001-05-31
GBGB0113232.3A GB0113232D0 (en) 2001-05-31 2001-05-31 Chemical process

Publications (1)

Publication Number Publication Date
ES2256493T3 true ES2256493T3 (es) 2006-07-16

Family

ID=9915637

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02747330T Expired - Lifetime ES2256493T3 (es) 2001-05-31 2002-05-29 Procedimiento para la preparacion de un ligando tiazol ppar y polimorfos del mismo.

Country Status (22)

Country Link
US (1) US7244849B2 (cg-RX-API-DMAC7.html)
EP (1) EP1395572B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004532265A (cg-RX-API-DMAC7.html)
KR (1) KR20040007631A (cg-RX-API-DMAC7.html)
CN (1) CN1551871A (cg-RX-API-DMAC7.html)
AT (1) ATE315556T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002317764B2 (cg-RX-API-DMAC7.html)
BR (1) BR0209892A (cg-RX-API-DMAC7.html)
CA (1) CA2448101A1 (cg-RX-API-DMAC7.html)
CO (1) CO5540298A2 (cg-RX-API-DMAC7.html)
CZ (1) CZ20033256A3 (cg-RX-API-DMAC7.html)
DE (1) DE60208682T2 (cg-RX-API-DMAC7.html)
ES (1) ES2256493T3 (cg-RX-API-DMAC7.html)
GB (1) GB0113232D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0400117A3 (cg-RX-API-DMAC7.html)
IL (1) IL158641A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03010943A (cg-RX-API-DMAC7.html)
NO (1) NO20035313L (cg-RX-API-DMAC7.html)
NZ (1) NZ529486A (cg-RX-API-DMAC7.html)
PL (1) PL367114A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002096893A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200308570B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
CN1662487A (zh) 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
EP1734930A2 (en) * 2004-04-09 2006-12-27 Smithkline Beecham Corporation Low dose pharmaceutical products
US20090012133A1 (en) * 2006-01-10 2009-01-08 Smithkline Beecham Corporation Polymorphic Form of -Acetic Acid
WO2012168948A2 (en) * 2011-06-06 2012-12-13 Hetero Research Foundation Process for febuxostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ グループ リミテッド hPPARアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
GB0113233D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
WO2002096893A1 (en) 2002-12-05
ZA200308570B (en) 2005-02-03
DE60208682T2 (de) 2006-08-24
HUP0400117A3 (en) 2005-09-28
PL367114A1 (en) 2005-02-21
US7244849B2 (en) 2007-07-17
NO20035313L (no) 2003-12-09
IL158641A0 (en) 2004-05-12
US20040242657A1 (en) 2004-12-02
CO5540298A2 (es) 2005-07-29
CZ20033256A3 (en) 2004-04-14
NZ529486A (en) 2005-12-23
MXPA03010943A (es) 2004-02-27
JP2004532265A (ja) 2004-10-21
EP1395572B1 (en) 2006-01-11
CA2448101A1 (en) 2002-12-05
CN1551871A (zh) 2004-12-01
DE60208682D1 (de) 2006-04-06
ATE315556T1 (de) 2006-02-15
KR20040007631A (ko) 2004-01-24
NO20035313D0 (no) 2003-11-28
GB0113232D0 (en) 2001-07-25
EP1395572A1 (en) 2004-03-10
BR0209892A (pt) 2004-06-08
HUP0400117A2 (hu) 2005-03-29
AU2002317764B2 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
AU758758B2 (en) Substituted oxazoles and thiazoles derivatives as HPPAR alpha activators
US5789428A (en) Amino-acid amide derivatives, processes for preparing the same, agricultural or horticultural fungicides, and method for killing fungi
ES2215626T3 (es) N-cianomethil amidas como inhibidores de proteasas.
CH688551A5 (it) 1,4-Diammino-2-idrossibutani sostituiti
JP4898052B2 (ja) 8a位で置換された8,8a−ジヒドロ−インデノ[1,2−d]チアゾール誘導体、その製造方法及び医薬、例えば食欲抑制薬としてのその使用
US9260421B2 (en) Pharmaceutical intermediates and process for the preparation thereof
WO2003097617A1 (en) Cysteine protease inhibitors
EP1395572B1 (en) Process for preparing a thiazole ppar-ligand and polymorphs thereof
CZ307826B6 (cs) Způsob přípravy N-[4-(2-{[2-(4-methansulfonamidofenoxy)ethyl](methyl)amino}ethyl)fenyl]methansulfonamidu (Dofetilidu)
CZ20011506A3 (cs) Omega-amidy N-arylsulfonylaminokyselin, způsob jejich přípravy a léčivo, které je obsahuje
JPS6332073B2 (cg-RX-API-DMAC7.html)
WO2001023350A1 (fr) Derives de thioalkylamine et methode de preparation desdits derives
AU2002317764A1 (en) Process for preparing a thialzole PPAR-ligand and polymorphs thereof
TW200825056A (en) New compounds
JP2001163854A (ja) チオアルキルアミン誘導体及びその製造方法
JP4027093B2 (ja) 2−アミノメチル−4−シアノチアゾールの製造方法
RU2698202C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПРЯМОГО ИНГИБИТОРА ФАКТОРА Ха
CA2380084C (en) A process for preparing 2-aminomethyl-4-cyano-thiazole
RU2263669C2 (ru) Замещенные 8,8a-дигидро-3ah-индено [1,2-d] тиазолы, способ их получения и их применение в качестве лекарственных средств
WO2014164844A1 (en) Cathepsin inhibitors